Roche's PD-L1+TIGIT dual target is used in the first-line NSCLC treatment, the effect is amazing, and the risk of OS death is reduced by 71%

On December 10, Roche announced the latest data on the PD-L1 antibody + TIGIT antibody combined with the first-line treatment of NSCLC Phase II clinical CITYSCAPE

NSCLC

At the ASCO meeting last year , Roche announced ORR, PFS and other treatment data for the clinical study

ASCO

The key data of this update is the hard endpoint OS.

The safety data of the combination therapy are as follows

This experiment also proved that the simultaneous targeting of immunosuppressive receptors TIGIT and PD-L1 can potentially amplify the immune response to enhance anti-tumor activity

This experiment also proved that the simultaneous targeting of immunosuppressive receptors TIGIT and PD-L1 can potentially amplify the immune response to enhance anti-tumor activity

Summary summary

PD-(L)1+TIGIT combination therapy has become a focus of competition among pharmaceutical companies.

About TIGIT antibody

About TIGIT antibodyAbout TIGIT antibody

On the surface of T lymphocytes, there are many important functional regulatory molecules, which are of great significance to the activation, proliferation and anti-tumor effects of T cells

On the surface of T lymphocytes, there are many important functional regulatory molecules, which are of great significance to the activation, proliferation and anti-tumor effects of T cells

We know that CD8+ T cells and NK cells are the effector cells that mainly kill tumor cells in the tumor microenvironment
.
TIGIT protein is expressed on the membranes of CD8+ T cells and NK cells.
After being activated by its ligand CD155 (PVR) or CD112 (usually expressed on the surface of tumor cells), it can inhibit the immune killing of CD8+ T cells and NK through the transmission of signal pathways.
Active, so that tumor cells escape the killing of immune cells
.
In addition, TIGIT has increased expression on regulatory T cells (Tregs, suppressive immune cells), especially tumor-infiltrating Tregs, which promotes its immunosuppressive function, secretes immune factors, and creates an immune tolerance microenvironment.
Promote tumor cells to evade immune killing
.
Therefore, through the application of TIGIT antibody to block the immune tolerance induced by TIGIT protein, it is expected to improve the body's anti-tumor immune function
.
Source: Medical notes Source: Medical notes

leave a message here